𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The efficacy of cholinergic drugs in patients with Alzheimer's disease—focus on the aminoacridines

✍ Scribed by K. Siegfried

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
776 KB
Volume
10
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The article reviews evidence for the efficacy of the aminoacridines (tacrine, velnacrine) in patients with probable Alzheimer's disease (AD). The discussion revolves around the question of the clinical relevance of the treatment effects observed. Other questions discussed deal with the heterogeneity of the patient population having AD, the size of the potential reponder group and the limitations caused by safety problems of these compounds. The conclusion is that the effects of the aminoacridines appear to have clinical relevance in a subgroup of patients with AD. These compounds therefore truly deserve the label of ‘first‐generation AD agents’. But further basic and clinical research is needed to identify the responder group and predict response.

📜 SIMILAR VOLUMES

Measuring the effects of anti-dementia d
Measuring the effects of anti-dementia drugs in patients with Alzheimer's disease
✍ S. Curran; J. P. Wattis 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 2 views

A large number of experimental compounds are being developed for the treatment of patients with Alzheimer's disease (AD). As dierent compounds may have dierent eects on CNS function, depending on which neurotransmitters they aect, adequate pro®ling will require the use of several tests. The dicultie

Clinical trials with the cholinergic dru
Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT)
✍ Albert Wettstein; René Spiegel 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 216 KB

The muscarinic agonist RS 86 was administered to patients with Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT) in a series of controlled clinical trials. Daily doses were up to 3.0 mg orally for a maximum duration of 18 weeks. RS 86 produced typical peripheral cholinergic e

Evidence for the presence of antibodies
Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease
✍ P. Foley; H. F. Bradford; M. Docherty; H. Fillit; V. N. Luine; B. McEwen; G. Buc 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 638 KB

A blind study showing that serum from patients with Alzheimer's disease causes immunolysis of mammalian brain synaptosomes is reported. Control, aged-matched, sera were largely without effect. The immunolysis was directed mainly against cholinergic synaptosomes. The data presented support the hypoth

The social consequences for families wit
The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment
✍ Anders Wimo; Bengt Winblad; Margareta Grafstrom 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 2 views

The social consequences of Alzheimer's disease are highlighted in this review with regard to impact on family situation, a changing treatment context caused by demographic changes, reorganization of long-term care, a ®nancial crisis in the public health systems and the introduction of antidementia d